http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
-
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
-
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
-
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
-
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
-
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
-
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
-
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
-
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
-
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
-
Molecular Partners Publishes Invitation to Annual General Meeting 2023
-
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
-
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
-
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
-
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
-
Molecular Partners (MOLN) Commences Phase 1 Trial for MP0533
-
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
-
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
-
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
-
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
-
Molecular Partners AG (MOLN) Presents Positive Interim Safety and Mechanistic Data From Phase 1 Trial of MP0317
-
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
-
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
-
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
-
Molecular Partners AG (MOLN) Announces CFO Departure
-
Molecular Partners AG (MOLN) Issues Clinical Development Updates
-
Molecular Partners Announces Planned Departure of Chief Financial Officer
-
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated b
-
Molecular Partners Reports Corporate Highlights and H1 2022 Financials
-
Molecular Partners Half Year 2022 News Release and Investor Call Details
-
Molecular Partners AG (MOLN) Reports Publication Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2
-
Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2
-
Molecular Partners Announces Participation in Scientific Conferences
-
Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum
-
Molecular Partners to Participate in Upcoming Healthcare Investor Conferences
-
Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association
-
Molecular Partners AG (MOLN) to Regains Global Rights for MP0310 from Amgen
-
Molecular Partners to Regain Global Rights for MP0310 from Amgen
-
Molecular Partners AG (MOLN) Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
-
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
-
Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022
-
Molecular Partners to Present at Kempen Life Sciences Investor Conference
-
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
-
Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research
-
Molecular Partners Publishes Invitation to Annual General Meeting 2022
-
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
-
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
-
Molecular Partners to Present at Upcoming Healthcare Investor Conference
-
Molecular (MOLN) Announces Emergency Use Authorization Request for Ensovibep Submitted to the FDA
-
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
